Our 500 animals are raised under exceptional sanitary conditions, with one ambition: paving the way for animal-to-human organ transplantation. The report highlights the concrete challenges of xenotransplantation in France. It also showcases what XENOTHERA, at the heart of the XENOCURE consortium, is already developing today, notably its LIS1 antibody, administered during allografts to neutralize the immune system’s immediate response. It has received orphan drug designation in both the United States and Europe.

April, 2026. In collaboration with CR2TI in Nantes (Center for Research in Transplantation and Translational Immunology), XENOTHERA presented the anti-cancer activity of XON11, its innovative treatment targeting pancreatic cancer, derived from its GH-pAbs technology platform (glyco-humanized polyclonal antibodies), at the Cancer Research Center of Marseille Congress.

October, 2025. Nantes-based biotech company XENOTHERA is accelerating its developments in oncology with several multispecific glyco-humanized antibody (GH-pAb) programs. The company today announces new clinical milestones and major publications